INDGN · Industrials · 2026-08-07

Indegene Ltd

Stage 3 · wk 2In scan: Prop Scan · Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹554.5
+0.77% today
₹13,336 Cr · Mid cap
About this companyIndustrials· Business Support Services
Expand ▾

Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.

Visit company website →
P/E (TTM)
31.2
Forward 19.6
Earnings Growth (YoY)
-32.3%
Revenue +32.8%
ROE
+13.9%
Profit margin +11.4%
Dividend Yield
0.39%
P/B 4.0
vs 52W High
-6.0%
₹423.5 lo₹589.6 hi
6.0% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 2
1w13w26w
Week 2 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
9.6%
200 DMA: ₹505.8 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
2.75x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↗ ⇈
Accelerating · MA20 +2.5% vs MA50 -0.2% / 10d
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Industrials
↓ Peaking
Stage 2%
36.4%
20d Δ
-2.5pp
1M return
+3.2%
3M return
+5.3%
Sector Stage-2 % · last 20 days
Sector has 157 Stage 2 leaders. See Industrials Stage 2 →
Industry
Business Support Services
↑ Building
Stage 2%
47.4%
20d Δ
+2.9pp
1M return
+6.6%
3M return
+8.9%
Industry Stage-2 % · last 20 days
Industry has 8 Stage 2 leaders. See Business Support Services Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2024-05-13 → 2026-08-07
S? 41w
S4 12w
S1 10w
S4 39w
2024-05-132026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S4 12w → S1 10w → S4 39w → S1 7w → S2 5w → S3 2w current
Total tracked: 116 weeks across 7 stage runs.
1M
+11.8%
3M
+4.6%
6M
+13.0%
YTD
+6.2%
1Y
+1.5%
Scan Membership
Prop Scan
Latest: 2026-06-30
Breakout Watch
Latest: 2026-06-24
5 appearances in last 60 days. First seen: 2026-06-24.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S3
Wk 2 · Vol —x
2026-08-06S3
Wk 2 · Vol —x
2026-08-05S3
Wk 2 · Vol —x
2026-08-04S3
Wk 2 · Vol —x
2026-08-03S3
Wk 1 · Vol —x
2026-07-31S3
Wk 1 · Vol —x
2026-07-30S3
Wk 1 · Vol —x
2026-07-29S3
Wk 1 · Vol —x
2026-07-28S32→3
Wk 1 · Vol —x
2026-07-27S2
Wk 5 · Vol —x
2026-07-24S2
Wk 5 · Vol —x
2026-07-23S2
Wk 5 · Vol —x
Sector Peers — Stage 2All →
DIACABS
wk 12 · 0.0% from hi
9.6
ATALREAL
wk 13 · 0.0% from hi
9.3
KAPSTON
wk 10 · -1.5% from hi
9.0
IL&FSENGG
wk 8 · -0.3% from hi
8.9
KABRAEXTRU
wk 7 · -6.1% from hi
8.8
Moving averages & range
50 DMA
₹516.3
200 DMA
₹505.8
52W High
₹589.6
52W Low
₹423.5
5D Low
₹540.3
Resistance levels (recent highs)
20d High
₹554.5
60d High
₹554.5
120d High
₹554.5
250d High
₹589.6
Next resistance
+6.3%
to 250d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.